biologics
R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
Investing in biologics excellence
Eloise McLennan
Antonio Magnelli, biologics, Chiesi Group, Sustainability
0 Comment
News/ News/ Sales and Marketing
Eli Lilly plans €400m Irish plant that will create 800 jobs
Phil Taylor
Alzheimer's disease, biologics, donanemab, Eli Lilly, IDA Ireland, Ireland, manufacturing
0 Comment
R&D/ Views & Analysis/ Views and analysis
Arecor heads for London Stock Exchange with drug reformulation strategy
Market Access/ Views & Analysis/ Views and analysis
Ireland is open: The biologics boom boosting the Irish economy
Catherine Longworth
biologics, country focus, FDI, IDA Ireland, Ireland
0 Comment
Sales and Marketing/ Views & Analysis/ Views and analysis
Nine for 2021: Addressing the pandemic legacy
mike.hammerton@pharmaphorum.com
2021, biologics, biosimilars, China, CNS, customer engagement, Nine for 2021
0 Comment
Market Access/ News/ News/ Top stories
US eyes faster launch for biosimilars in North American trade pact; reports
Phil Taylor
biologics, biosimilars, Canada, Mexico, trade, usa
0 Comment
Events/ Events/ Partner Content
Drug Delivery & Formulation Summit 2019
diogo.ribeiro@epmgroup.org
biologics, biosimilars, drugdelivery, drugdevelopment, formulation
0 Comment
innovation and breakthroughs at all levels at DDF’19